|
Last Updated: Nov 17th, 2006 - 22:35:04 |
Latest Research
:
Immunology
:
Autoimmune Diseases
:
Lupus
Pregnant women with lupus are at higher risk for complications
Women with systemic lupus who become pregnant are at significantly greater risk for death or other medical complications than are pregnant women without lupus, Duke University Medical Center researchers have found in a nationwide study of more than 18 million women.
Nov 12, 2006, 16:21
Latest Research
:
Immunology
:
Autoimmune Diseases
:
Lupus
Oral Contraceptives in Women with Lupus might be Safe
In a major study funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), women with either inactive or stable systemic lupus erythematosus (lupus) � a disease in which the body�s immune system mistakenly attacks and damages healthy tissues of the skin, joints and internal organs � were able to take oral contraceptives without increased risk of flares, or periods of increased disease activity, that characterize the disease. Safe and effective contraception is an issue that many women of childbearing age face. But for women with lupus, doctors have often been hesitant to prescribe one of the most effective forms of contraception � oral contraceptives, or the �pill� � for fear that it might increase disease activity.
Dec 25, 2005, 00:59
Latest Research
:
Immunology
:
Autoimmune Diseases
:
Lupus
Pro-inflammatory HDL (piHDL) is a potential biomarker for lupus atherosclerosis
Groundbreaking research reported at the annual meeting of the American College of Rheumatology indicates that a certain form of the normally "good" high density lipoprotein (HDL) cholesterol linked to cardiovascular health plays a counterproductive role in people with systemic lupus erythematosus (SLE) and rheumatoid arthritis, promoting atherosclerosis (hardening of the arteries) and heart disease in many of these individuals.
Nov 16, 2005, 19:27
Latest Research
:
Immunology
:
Autoimmune Diseases
:
Lupus
Epratuzumab may Serve as a Potential Treatment Option for SLE
Immunomedics Inc announced patient dosing has begun for the pivotal Phase III clinical trials to further evaluate the safety and efficacy of the Company's lead drug candidate, epratuzumab, for the treatment of patients with systemic lupus erythematosus (SLE), known as lupus.
Jun 6, 2005, 10:10
Latest Research
:
Immunology
:
Autoimmune Diseases
:
Lupus
How lupus T cells lose IL-2
Lupus is a chronic, autoimmune disease that causes inflammation, particularly of the skin, joints, blood, and kidneys.
Apr 3, 2005, 13:11
|
